Medicine and Health
Preliminary trials in both humans and dogs demonstrate the potential efficacy of an mRNA-based vaccine for brain cancer
A novel mRNA vaccine candidate for highly malignant brain cancer has exhibited encouraging results in a limited-scale clinical trial, albeit with a unique approach. In addition to conducting vaccine trials on a small number of human cancer patients, the researchers are also utilizing data from 10 pet dogs.
It is customary for drugs and treatments intended for human use to undergo animal trials initially. Frequently, this phase of the process occurs subsequent to laboratory experiments conducted on cells but prior to any involvement of human volunteers in the administration of the drug. Despite ongoing endeavors to diminish animal testing and substitute it with alternative methods, it remains a fundamental component of pharmaceutical research.
Typically, however, our intention is not to medically treat animals for a disease they acquired in a natural manner. Scientists create models in species with organ systems that closely resemble those of humans, utilizing drugs, surgery, or genetic modification to imitate human diseases.
In the context of this mRNA vaccine, that stage was accomplished in mice. However, there was an additional, atypical measure. Dogs are the exclusive nonhuman species that are susceptible to the occurrence of spontaneous brain tumors. This makes them a valuable resource for testing treatments in a more authentic environment.
Ten pet dog owners granted consent for their canines to participate. Glioma, a type of cancer, is universally lethal, making this trial their sole available treatment option. In contrast to the typical average survival time of 30–60 days following a diagnosis, the dogs experienced a median survival of 139 days after receiving the vaccine, allowing for a significant increase in opportunities for treats and belly rubs.
Following successful outcomes in both the mice and the dogs, the researchers proceeded to administer the vaccine to four human patients diagnosed with glioblastoma. This is the most malignant type of brain cancer, characterized by a low rate of survival.
At present, it is premature to have a comprehensive understanding of the clinical impacts of the vaccine. However, it is established that all patients experienced either a prolonged period without illness or a longer-than-anticipated survival rate. The results are so encouraging that a larger Phase I trial is now scheduled to encompass both pediatric and adult populations.
What is the mechanism of action of the vaccine?
As observed in previous advancements in this field, one significant benefit of mRNA-based vaccines for cancer is their ability to be customized for individual patients. The glioblastoma vaccine incorporates this feature alongside a pioneering delivery system.
“Rather than injecting individual particles, we are injecting clusters of particles that are coiling around each other, similar to onions in a bag,” explained Dr. Elias Sayour, senior author from the University of Florida, in a statement. “The rationale behind this approach in the context of cancer is that these clusters stimulate the immune system to a greater extent than individual particles.”
Due to the COVID-19 pandemic, we have gained a greater understanding of mRNA vaccines; however, the mechanisms behind their functioning differ slightly. The RNA is obtained from the tumor cells of each patient and then enclosed in a lipid nanoparticle “costume.”. Upon reintroduction into the bloodstream, the immune system perceives this substance as a virus, thereby preparing itself to react to any remaining cancerous cells.
The process of personalization customizes the vaccine to suit the individual patient, thereby optimizing its effectiveness. Additionally, the delivery system enhances the immune system’s ability to respond quickly.
“Within a span of less than 48 hours, we may witness a transformation of these tumors from an ‘immune cold’ state, characterized by a scarcity of immune cells and a suppressed immune response, to an ‘immune hot’ state, marked by a highly active immune response,” Sayour noted.
“The study’s discovery that producing an mRNA cancer vaccine in this manner elicits comparable and robust reactions in mice, pet dogs with naturally occurring cancer, and human patients with brain cancer is a highly significant finding. This is because it is often uncertain how well the results of preclinical studies in animals will translate into similar responses in patients,” stated Dr. Duane Mitchell, a co-author of the study.
Sayour stated that the vaccine has the potential to be integrated with other immunotherapies as part of a combined treatment. “I am optimistic that this could represent a novel paradigm for patient treatment, a cutting-edge platform technology for modulating the immune system,” he stated.
The research findings have been published in the scientific journal Cell.
Medicine and Health
A recently identified strain of deadly fungus poses a significant risk to public health
Researchers have recently discovered a new group of Candida auris, a potentially dangerous pathogen. The finding increases the total number of identified clades of the fungus, which is a newly emerging superbug resistant to multiple drugs, to six.
Candida auris is a strain of yeast that has the potential to cause serious illness and is frequently impervious to antifungal drugs. While individuals who are in good health generally do not fall ill, the transmission of the disease is highly prevalent within medical institutions and poses a significant risk to individuals with compromised immune systems. The yeast can induce a variety of conditions ranging from superficial infections of the skin to more severe and life-threatening illnesses, such as bloodstream infections. Due to its high level of resistance to multiple drugs, treating it can be challenging, and in some cases, even impossible.
The authors state that the pathogen is a significant global public health threat due to its widespread distribution, resistance to multiple drugs, high ability to spread, tendency to cause outbreaks, and high mortality rate. Although infections are still relatively uncommon, there has been a significant increase in cases in recent years.
Previously, the fungus had been categorized into five distinct clades, each located in different geographic regions: South Asia, East Asia, Africa, South America, and Iran.
In April 2023, doctors from the Singapore General Hospital identified a patient carrying a unique strain of C. auris as part of a routine screening program, adding it as the most recent clade to be discovered. Typically, these cases arise from individuals who have recently traveled, but this particular patient had not traveled outside the country for a period of two years, which raised some concerns.
Upon conducting a genetic analysis of the strain, the researchers determined that it did not align with any of the five known clades of the fungus. Therefore, it can be concluded that the strain belongs to a previously unidentified, sixth clade. Subsequently, they conducted tests on strains obtained from previous patients and identified two additional isolates of this particular group of C. auris in Singapore, as well as another isolate in Bangladesh.
The extent of the new clade’s prevalence and its potential to cause invasive infections and outbreaks remains uncertain at present. However, the researchers emphasize the importance of promptly identifying and controlling it in order to safeguard patient well-being.
“The ramifications of this breakthrough transcend the confines of the laboratory.” “Given the recent discovery of the sixth Candida auris clade, it is imperative to enhance surveillance capability or create new methods to strengthen existing surveillance strategies. This will enable health care facilities to closely monitor its emergence and effectively control its spread,” stated Dr. Karrie Ko, co-first author of the study.
Fortunately, the cases described in the study remained vulnerable to all antifungals that were tested. This should alleviate concerns about a pandemic similar to the one depicted in The Last Of Us. However, it is evident that the threat of C. auris is persistent. Therefore, additional efforts are required to identify new strains, monitor their spread, and control any negative clinical consequences.
The research is published in The Lancet Microbe journal.
Medicine and Health
What makes your chest hurt when something makes you jump?
Have you ever been scared so badly that you grabbed your chest? You feel like someone or something just zapped you behind the sternum. As you rest, you lean against the wall and think about why your friend is such a jerk and why you can feel it in your chest whenever you get scared.
People often use words like “heart-stopping” when they write fiction about fear, but the science of fear tells us that this isn’t what’s happening because it wouldn’t make sense. Our bodies are getting ready to deal with an impending threat when we’re scared, and going into cardiac arrest wouldn’t help us get very far if a lion was after us.
What do we do when we’re scared?
The sympathetic nervous system is what gets you excited when something makes you jump. It’s a tool inside our bodies that releases hormones and changes the way our bodies work to get us ready for the fight-or-flight response.
One important part is adrenaline, which is also known as epinephrine. The adrenal glands squeeze it out into the blood. The heart starts beating faster, sending more blood to your muscles and organs right away. Because they need all the oxygen they can get if they want to get away from a dangerous animal.
How do you feel when you go for a run?
Anyone who has ever used an EpiPen knows how bad it is to feel a sudden rush of adrenaline. It’s a stress hormone that makes you feel nervous and anxious, like you would before doing a bungee jump. Getting a rush when you think about a traumatic event from the past can be a sign of PTSD.
A medicine called adrenaline is used because it can help people who are having a medical emergency. If you have anaphylaxis from an allergen like peanuts, this can help because it can open your airway. Because it changes the strength and speed of heartbeats, it is also sometimes used to help people who are having a cardiac arrest.
When your adrenaline level goes up quickly, you may feel shaky, your heart beat quickly, and your chest get tight. When you add in the fact that you’re more alert, you become very aware of the changes in your body. This is especially clear when you’re not in danger, like when your partner surprised you at home when you thought you were alone.
When you’re scared, your sympathetic nervous system usually kicks in, which is normal. But, some heart conditions can get worse when you’re scared. Should anyone be having chest pain or ongoing discomfort, they should see a doctor. In the end, it is possible to be so scared that you die.
This article is not meant to be a replacement for medical advice, diagnosis, or treatment from a trained professional. If you have questions about a medical condition, you should always talk to a qualified health professional.
Medicine and Health
The Lacks family is suing again over her “stolen” cells
The family of Henrietta Lacks has filed a new lawsuit against two sizable drug companies for using her genetic material without her consent.
In the US District Court for the District of Maryland, Lacks’ living relatives are suing Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc., Viatris, Inc., and its subsidiary, Mylan Pharmaceuticals. They say the companies have used the “stolen” HeLa cell line to make hundreds of patents and have made a lot of money from it.
The suit wants the money made from using these cells to be “rightfully transferred” to Henrietta Lacks’s estate.
Novartis and Viatris chose to sell Henrietta Lacks’ living genetic material. Lacks was a black grandmother, community leader, and woman whose doctors took her tissue without her knowledge or permission, according to Chris Ayers, an attorney at Seeger Weiss LLP who is representing the Lacks family.
Ayers added, “We will keep looking for justice for Mrs. Lacks and her family.”
Henrietta Lacks died on October 4, 1951, from cervical cancer. She was 31 years old. Some of her cells are still alive today. A doctor at Johns Hopkins Hospital took a sample of her cervical cells without her knowledge just before she died. They were doing a cancer check. It was seen that her cells kept multiplying quickly, even after most of the cells in other samples would have died without their host.
Because scientists saw the potential, they found that these cells could be a cheap and easy way to help researchers do more research. The “HeLa immortal cell line” is what scientists call these cells, and they are very useful for biomedical research.
Over 75,000 scientific studies around the world have used these cells, which amount to about 55 million tons. They have been very important in making progress in areas like polio vaccines, cancer treatments, HIV/AIDS treatments, and much more.
All of this was done, though, without Lacks’ knowledge or permission. For many years, her family also didn’t know that the cells were being used for business.
Selling HeLa cells for money brings up important issues in medical ethics and genetics. As a black woman living in America in the 1950s, Lacks’ case shows how medical racism still affects minorities who aren’t getting enough help.
Even though a lot of people know about these problems, HeLa cells are still used in medical research for profit, which makes some companies a lot of money.
“Now that everyone knows Henrietta Lacks’ story, it’s shocking, but not surprising, that drug companies like Novartis and Viatris are still making money off of the deeply unethical origins of HeLa cells and the disturbing history of medical racism,” said Chris Seeger, another lawyer for the family.
A historic deal was made by Lacks’ family in 2023 after they sued Thermo Fisher Scientific, Inc., another biotech company, in the US District Court for the District of Baltimore. During that time, the lawyers said that the settlement was only the beginning and that there could be many more lawsuits about the use of HeLa cells.
- Gadgets10 years ago
Why the Nexus 7 is still a good tablet in 2015
- Mobile Devices10 years ago
Samsung Galaxy Note 4 vs Galaxy Note 5: is there room for improvement?
- Editorials10 years ago
Samsung Galaxy Note 4 – How bad updates prevent people from enjoying their phones
- Mobile Devices9 years ago
Nexus 5 2015 and Android M born to be together
- Gaming10 years ago
New Teaser For Five Nights At Freddy’s 4
- Mobile Devices9 years ago
Google not releasing Android M to Nexus 7
- Gadgets10 years ago
Moto G Android 5.0.2 Lollipop still has a memory leak bug
- Mobile Devices9 years ago
Nexus 7 2015: Huawei and Google changing the game